Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Peter B. Langmuir, MD
Incyte Corporation
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
17 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of California San Francisco Helen Diller Family Comprehensive Cancer Center
San Francisco, California, United States
- John Wayne Cancer Institute at Providence Saint John'S Health Center
Santa Monica, California, United States
- Georgetown University Medical Center Lombardi Ccc
Washington D.C., District of Columbia, United States
- Hematology-Oncology Associates of Treasure Coast
Port Saint Lucie, Florida, United States
- Emory University, Winship Cancer Institute
Atlanta, Georgia, United States
- University of Kentucky, Markey Cancer Center
Lexington, Kentucky, United States
- the Center for Cancer and Blood Disorders (rcca Md Llc-Maryland Vidision)
Bethesda, Maryland, United States
- Beth Israel Medical Deaconess Medical Center
Boston, Massachusetts, United States
- Dana Farber Cancer Institute
Boston, Massachusetts, United States
- Henry Ford Hospital System
Detroit, Michigan, United States
- Karmanos Cancer Center
Detroit, Michigan, United States
- St. Luke'S Hospital of Kansas City
Kansas City, Missouri, United States
- Nyu Laura & Isaac Perlmutter Cancer Center at Nyu Langone
New York, New York, United States
- Duke Cancer Institute
Durham, North Carolina, United States
- Upmc Cancercenters, Hilman Cancer Center
Pittsburgh, Pennsylvania, United States
- Hope Cancer Center of East Texas
Tyler, Texas, United States
- Utah Cancer Specialists
Salt Lake City, Utah, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 25 Jan 2016
- Primary completion
- 7 Nov 2019
- Completion
- 20 Nov 2020
- Last update posted
- 31 Mar 2022
- Registered enrollment
- 159
- Registry id
- NCT02646748
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.